Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer

Takaaki Tanaka; Masataka Taoka; Go Makimoto; Kiichiro Ninomiya; Hisao Higo; Masanori Fujii; Eiki Ichihara; Kadoaki Ohashi; Katsuyuki Hotta; Masahiro Tabata; Yoshinobu Maeda

doi:10.2169/internalmedicine.2429-23

Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer

Takaaki Tanaka, Masataka Taoka, Go Makimoto, Kiichiro Ninomiya, Hisao Higo, Masanori Fujii, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda

University Hospital

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.

Original language	English
Pages (from-to)	1261-1267
Number of pages	7
Journal	Internal Medicine
Volume	63
Issue number	9
DOIs	https://doi.org/10.2169/internalmedicine.2429-23
Publication status	Published - 2024

Keywords

cytokine release syndrome
immune checkpoint inhibitor
immune effector cell-associated neurotoxicity syndrome
ipilimumab
nivolumab

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.2429-23

Cite this

Tanaka, T., Taoka, M., Makimoto, G., Ninomiya, K., Higo, H., Fujii, M., Ichihara, E., Ohashi, K., Hotta, K., Tabata, M., & Maeda, Y. (2024). Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer. Internal Medicine, 63(9), 1261-1267. https://doi.org/10.2169/internalmedicine.2429-23

Tanaka, T, Taoka, M, Makimoto, G , Ninomiya, K , Higo, H , Fujii, M , Ichihara, E , Ohashi, K , Hotta, K , Tabata, M & Maeda, Y 2024, 'Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer', Internal Medicine, vol. 63, no. 9, pp. 1261-1267. https://doi.org/10.2169/internalmedicine.2429-23

@article{2db13041293e463ead59b7f1a41495d3,

title = "Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer",

abstract = "A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.",

keywords = "cytokine release syndrome, immune checkpoint inhibitor, immune effector cell-associated neurotoxicity syndrome, ipilimumab, nivolumab",

author = "Takaaki Tanaka and Masataka Taoka and Go Makimoto and Kiichiro Ninomiya and Hisao Higo and Masanori Fujii and Eiki Ichihara and Kadoaki Ohashi and Katsuyuki Hotta and Masahiro Tabata and Yoshinobu Maeda",

note = "Publisher Copyright: {\textcopyright} 2024 The Japanese Society of Internal Medicine.",

year = "2024",

doi = "10.2169/internalmedicine.2429-23",

language = "English",

volume = "63",

pages = "1261--1267",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "9",

}

TY - JOUR

T1 - Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer

AU - Tanaka, Takaaki

AU - Taoka, Masataka

AU - Makimoto, Go

AU - Ninomiya, Kiichiro

AU - Higo, Hisao

AU - Fujii, Masanori

AU - Ichihara, Eiki

AU - Ohashi, Kadoaki

AU - Hotta, Katsuyuki

AU - Tabata, Masahiro

AU - Maeda, Yoshinobu

PY - 2024

Y1 - 2024

N2 - A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.

AB - A 55-year-old man with stage IV lung adenocarcinoma was treated with cisplatin, pemetrexed, nivolumab, and ipilimumab. Approximately 100 days after treatment initiation, he became disoriented and presented to the emergency department with a high fever. Blood tests revealed liver and kidney dysfunctions. Subsequently, the patient developed generalized convulsions that required intensive care. He was clinically diagnosed with cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Organ damage was gradually controlled with immunosuppressive drugs, including steroids, and the patient was discharged. Successful treatment is rare in patients with CRS, including ICANS, during immune checkpoint inhibitor treatment for solid tumors.

KW - cytokine release syndrome

KW - immune checkpoint inhibitor

KW - immune effector cell-associated neurotoxicity syndrome

KW - ipilimumab

KW - nivolumab

UR - http://www.scopus.com/inward/record.url?scp=85176115684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85176115684&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.2429-23

DO - 10.2169/internalmedicine.2429-23

M3 - Article

C2 - 37722894

AN - SCOPUS:85176115684

SN - 0918-2918

VL - 63

SP - 1261

EP - 1267

JO - Internal Medicine

JF - Internal Medicine

IS - 9

ER -

Severe Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome in a Man Receiving Immune Checkpoint Inhibitors for Lung Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this